Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD16-positive, CD56-dim natural killer cell, human | 12 studies | 21% ± 5% | |
macrophage | 10 studies | 33% ± 12% | |
microglial cell | 9 studies | 33% ± 14% | |
natural killer cell | 7 studies | 22% ± 5% | |
dendritic cell | 7 studies | 30% ± 11% | |
classical monocyte | 6 studies | 27% ± 11% | |
non-classical monocyte | 6 studies | 26% ± 9% | |
monocyte | 6 studies | 26% ± 9% | |
myeloid cell | 6 studies | 25% ± 7% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 19% ± 2% | |
lymphocyte | 4 studies | 22% ± 6% | |
conventional dendritic cell | 3 studies | 34% ± 15% | |
CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
alveolar macrophage | 3 studies | 27% ± 9% | |
mast cell | 3 studies | 22% ± 4% | |
plasmacytoid dendritic cell | 3 studies | 25% ± 7% |
Insufficient scRNA-seq data for expression of ADCY7 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 1565.40 | 576 / 578 | 97% | 7.38 | 1123 / 1155 |
esophagus | 96% | 653.75 | 1389 / 1445 | 99% | 8.91 | 181 / 183 |
intestine | 93% | 539.21 | 901 / 966 | 91% | 4.24 | 482 / 527 |
ovary | 99% | 1306.17 | 179 / 180 | 84% | 3.49 | 360 / 430 |
skin | 100% | 1249.89 | 1803 / 1809 | 82% | 3.58 | 388 / 472 |
stomach | 77% | 241.98 | 276 / 359 | 95% | 5.09 | 273 / 286 |
breast | 86% | 337.71 | 394 / 459 | 86% | 4.04 | 959 / 1118 |
bladder | 86% | 291.00 | 18 / 21 | 71% | 3.41 | 360 / 504 |
uterus | 70% | 211.43 | 119 / 170 | 79% | 3.90 | 361 / 459 |
thymus | 81% | 320.43 | 528 / 653 | 66% | 2.37 | 400 / 605 |
brain | 42% | 134.38 | 1102 / 2642 | 94% | 4.80 | 660 / 705 |
pancreas | 37% | 91.62 | 120 / 328 | 90% | 5.11 | 160 / 178 |
kidney | 38% | 152.91 | 34 / 89 | 77% | 3.28 | 698 / 901 |
adrenal gland | 84% | 349.43 | 217 / 258 | 25% | 0.53 | 57 / 230 |
prostate | 67% | 205.44 | 164 / 245 | 35% | 0.68 | 178 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 9.76 | 29 / 29 |
spleen | 100% | 2043.16 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1894.22 | 921 / 929 | 0% | 0 | 0 / 0 |
adipose | 97% | 576.88 | 1162 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 88% | 463.95 | 1179 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 5.12 | 39 / 45 |
heart | 72% | 310.71 | 623 / 861 | 0% | 0 | 0 / 0 |
liver | 29% | 77.20 | 65 / 226 | 26% | 0.71 | 105 / 406 |
eye | 0% | 0 | 0 / 0 | 31% | 0.55 | 25 / 80 |
muscle | 15% | 31.29 | 117 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1900016 | Biological process | negative regulation of cytokine production involved in inflammatory response |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0006171 | Biological process | cAMP biosynthetic process |
GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
GO_0071361 | Biological process | cellular response to ethanol |
GO_0002819 | Biological process | regulation of adaptive immune response |
GO_0060135 | Biological process | maternal process involved in female pregnancy |
GO_0071285 | Biological process | cellular response to lithium ion |
GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0016020 | Cellular component | membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0004016 | Molecular function | adenylate cyclase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | ADCY7 |
Protein name | adenylate cyclase (EC 4.6.1.1) Adenylate cyclase type 7 (EC 4.6.1.1) (ATP pyrophosphate-lyase 7) (Adenylate cyclase type VII) (Adenylyl cyclase 7) Adenylate cyclase 7 |
Synonyms | KIAA0037 |
Description | FUNCTION: Catalyzes the formation of cAMP in response to activation of G protein-coupled receptors (Probable). Functions in signaling cascades activated namely by thrombin and sphingosine 1-phosphate and mediates regulation of cAMP synthesis through synergistic action of the stimulatory G alpha protein with GNA13 . Also, during inflammation, mediates zymosan-induced increase intracellular cAMP, leading to protein kinase A pathway activation in order to modulate innate immune responses through heterotrimeric G proteins G(12/13) (By similarity). Functions in signaling cascades activated namely by dopamine and C5 alpha chain and mediates regulation of cAMP synthesis through synergistic action of the stimulatory G protein with G beta:gamma complex . Functions, through cAMP response regulation, to keep inflammation under control during bacterial infection by sensing the presence of serum factors, such as the bioactive lysophospholipid (LPA) that regulate LPS-induced TNF-alpha production. However, it is also required for the optimal functions of B and T cells during adaptive immune responses by regulating cAMP synthesis in both B and T cells (By similarity). . |
Accessions | ENST00000564965.5 H3BMA5 ENST00000254235.7 ENST00000394697.7 ENST00000566433.6 H3BQ93 F5H699 ENST00000566761.2 F5H4D1 ENST00000537579.5 P51828 I3L2Y1 ENST00000567277.6 ENST00000673973.1 I3L3Q5 ENST00000569265.1 A0A669KBF7 ENST00000564044.5 ENST00000673801.1 |